Dendreon (NASDAQ:DNDN) has posted its results. The actual EPS and revenues don’t matter because of the stage of the company. But the company did lower its total expenses to $23.4 million. That compares to $26.3 million from Q2 2006 and roughly $28 million last quarter. Those expenses included options costs of $1.3 million and $2.9 million, respectively.
So the company slowed its cash burn rate, and that is what we wanted to see. Unfortunately the company made no new developments in the "highlights" or "disclosures." Unless the company announces some unexpected FDA developments or unless it announces a surprise partner, this one sounds like there could be a continued news vacuum.
Jon C. Ogg
August 7, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
